ArticleMetabolic brain disease2026
Role of the TLR4-NF-κB-FDX1 cuproptosis axis in mediating cognitive impairment associated with type 1 diabetes in children: an exploratory mechanistic study.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study explored how the TLR4-NF-κB-FDX1 cuproptosis axis contributes to type 1 diabetes (T1DM)-related cognitive impairment, seeking to uncover novel intervention targets. Key genes were screened from T1DM datasets via bioinformatics analysis. Primary hippocampal neurons, HBMECs, and a Transwell co-culture BBB model were established under high glucose plus copper overload. Cells received TLR4 inhibitor TAK-242 or FDX1 knockdown. A streptozotocin-induced T1DM mouse model was generated, followed by stereotaxic injection of TLR4-shRNA or FDX1-shRNA adenovirus. Cell viability, cuproptosis markers, BBB permeability, cognitive behaviors, and underlying mechanisms were assessed by CCK-8, ICP-MS, TEER, behavioral tests, Western blot, immunofluorescence, and ChIP-qPCR. FDX1 was markedly upregulated in T1DM and strongly correlated with TLR4/NF-κB. In vitro, high glucose plus copper overload activated the TLR4-NF-κB-FDX1 axis, induced DLAT lipoylation aggregation and cuproptosis, and caused neuronal synaptic injury along with disruption of endothelial tight junctions. Blocking TLR4 or knocking down FDX1 significantly attenuated these damages. In vivo, T1DM mice showed cognitive deficits and BBB disruption, both rescued by TLR4 or FDX1 knockdown. ChIP-qPCR confirmed that NF-κB bound directly to the FDX1 promoter to enhance its transcription. This study demonstrated for the first time that the TLR4-NF-κB-FDX1 cuproptosis axis plays a key pathological role in T1DM-related cognitive impairment, offering a new avenue for targeted therapy.
Indexed as
Identifiers
42560412What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.